Kytopen and aldevron expedite cell therapy manufacturing through their collaborative crispr-mediated cellular engineering workflow

Kytopen and aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. high transgene expression and improved safety profile of aldveron's nanoplasmid™  vector technology and the gentle gene-delivery of kytopen's flowfect tx™ platform with unlimited scale, together offer enhanced crispr-mediated t-cell engineering resulting in high yields.
DHR Ratings Summary
DHR Quant Ranking